Setmelanotide-mediated MC4R activation improves hypothalamic obesity via CaMKK2/AMPK pathways

Area of Science:

• Neuroscience
• Endocrinology
• Pharmacology

Background:

• Hypothalamic obesity (HO) is a severe condition resulting from central nervous system damage, with unclear mechanisms and no targeted drugs.
• Melanocortin 4 receptor (MC4R) agonists like setmelanotide show promise for genetic obesity, but their role in HO is unknown.

Purpose of the Study:

• To investigate setmelanotide's efficacy in treating hypothalamic obesity (HO) by targeting MC4R in the paraventricular nucleus (PVN).
• To elucidate the signaling pathways involved in MC4R dysfunction and setmelanotide's therapeutic effects in HO.

Main Methods:

• A rat model of hypothalamic injury was established to mimic HO symptoms.
• Immunofluorescence and immunoblot analysis were used to assess PVN neuropeptides and signaling pathways (CaMKK2, AMPK).
• Setmelanotide was administered to obese rats to evaluate its impact on feeding behavior and weight.

Main Results:

• Hypothalamic injury led to hyperphagia, weight gain, and inhibited MC4R signaling via CaMKK2/AMPK pathways.
• Setmelanotide treatment restored CaMKK2/AMPK activity and reactivated MC4R neurons.
• Setmelanotide significantly reduced food intake (60%) and body weight (23%) in obese rats, normalizing appetite.

Conclusions:

• MC4R dysfunction is critical in hypothalamic injury-induced obesity.
• Pharmacological activation of MC4R via CaMKK2/AMPK signaling is a viable strategy to restore metabolic homeostasis.
• Setmelanotide represents a potential therapeutic agent for managing obesity caused by central nervous system injury.